Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET-Reference-Cited by-同舟云学术

Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET

Published:2018 Issue: Volume: Page:187-198
ISSN:0080-0015
Container-title:Recent Results in Cancer Research
language:
Short-container-title:

Author:

Zschäbitz Stefanie,Grüllich Carsten

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-319-91442-8_13

Reference30 articles.

1. Boss DS et al (2012) A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 106(10):1598–1604. ISSN 1532-1827. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/22516948

2. Bruheim S et al (2011) Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. Int J Cancer 129(3):742–750. ISSN 1097-0215. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/21225632

3. Cabanillas ME et al (2015) A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 121(16):2749–2756. ISSN 1097-0142. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25913680

4. Finn RS, Cheng A-L, Ikeda K et al (2017) A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma. ASCO

5. Flaherty KT et al (2015) BEST: a randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma—a trial of the ECOG-ACRIN Cancer Research Group (E2804). J Clin Oncol 33(21):2384–2391. ISSN 1527-7755. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26077237

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database;British Journal of Clinical Pharmacology;2024-09-02

2. An insight into sustainable and green chemistry approaches for the synthesis of quinoline derivatives as anticancer agents;European Journal of Medicinal Chemistry;2024-09

3. Tyrosine Kinase Inhibitor Lenvatinib Causes Cardiotoxicity by Inducing Endoplasmic Reticulum Stress and Apoptosis through Activating ATF6, IRE1α and PERK Signaling Pathways;Recent Patents on Anti-Cancer Drug Discovery;2024-07-11

4. Breaking Down the Arsenal: Recent Progress in the Nanotherapeutic Strategies for Hepatocellular Carcinoma Treatment;Advanced Therapeutics;2024-07-06

5. The role of the methoxy group in approved drugs;European Journal of Medicinal Chemistry;2024-07